In partnership with rapper Snoop Dogg’s Leafs brand, Canopy Growth is ready to roll out three new strains of marijuana across Canada by the end of the month. That is exciting news for the recreational marijuana user in Canada, but what does it mean for the company’s earnings? The answer decides whether investors should expect significant share price gains . This company is one of the only producers turning a profit at $427,000 and $1.95 million in the fourth quarter last year and the first quarter, respectively. Aurora Cannabis achieved two major milestones in the past 30 days that one would expect of a young growth stock. Green Rush First, the company’s shares were moved to the Toronto Stock Exchange’s Venture Exchange. This milestone reflects “remarkably rapid operational and commercial progress,” Chief Executive Terry Booth said. Second, the company said this month that it will issue up to $25 million in convertible debt. This offering makes Aurora Cannabis one of the best capitalized companies in the cannabis sector, Booth said.
Despite these soaring sales, though, Canopy Growth stock has fallen around 10% so far in 2017. Granted, that’s relatively insignificant when you consider that the share price is still up over 190% since the beginning of last year. However, investors should know why the stock isn’t growing as much as its marijuana crops and revenue are. One reason is that Canopy Growth’s bottom-line performance doesn’t look as good. The company lost nearly $22 million in its fiscal fourth quarter compared to a loss of $5 million in the prior-year period. One reason behind this bigger loss was Canopy Growth’s acquisitions activity. However, it is also spending a lot more money than in the past on sales, marketing, and administrative functions. In addition, the Canadian government announced in May that it plans to make significant changes to the medical Marijuana Stocks cannabis program . Those changes include authorizing more providers to supply medical marijuana in the country.
CBD water promises to bring together the best of what pure water and CBD have to offer.
A handful of cannabis companies are coming up with innovative new ways to tap into the health benefits of cannabidiol (CBD). In particular, CBD-infused water is the latest product to hit the market. Now, CBD water could be the next trend to sweep the cannabis scene.
The Potential of CBD Water
CBD water is exactly what the name implies: CBD-infused water. The combination of pure water and CBD could have some impressive health and medicinal properties.
For starters, water is crucial for good health. In particular, staying hydrated is a key to pretty much every body function, and is important for maintaining your general well-being.
On top of that, researchers are discovering a number of health and medicinal properties associated with CBD.
In general, CBD is often thought of as the non-psychoactive complement to THC. That’s because it helps mellow out and counteract some of the potentially negative effects of THC.
But beyond that, it also produces a range of powerful effects on its own. So far, research has found that CBD can provide treatment for a number of health conditions. As evidence, here’s a quick rundown of what CBD can do:
CBD water brings all these health and medicinal properties together into a discreet, convenient, easy-to-use format.
You can drink it straight. Alternatively, you can add it to other drinks or snacks to turn pretty much anything you want into a CBD-infused edible.
New Innovations in the Cannabis Industry
CBD water could be the next big trend in the cannabis industry. More immediately, it represents the latest innovation to come out of the industry.
So far, there are already a handful of companies to bring CBD water to market. And many of them rely on some new technologies to make it happen.
Making CBD-infused water is actually a lot more complicated than it might at first sound. That’s largely because cannabinoids like THC and CBD don’t naturally bond well with water.
This means that cannabis companies had to come up with another way of making it happen. As a result, many CBD water products rely on “nano technology.”
CBD Living Water, one of a handful of companies now selling CBD water, said the process relies on “quantum physics” to reduce CBD “into tiny particles, one millionth of their size.” From there, the nano-sized CBD particles are encapsulated “in a water cluster.”
The company claims that this process doesn’t just provide a way to infuse water with CBD. According to the company’s website, those tiny particles of CBD are also more readily absorbed by your body. This, the company reports, helps optimize the medical potential of the cannabinoid.
Final Hit: CBD Water Could Be The Next Big Trend In Cannabis
CBD products are becoming a staple in the legal cannabis market. Researchers continue learning more about how this cannabinoid can be used as a health supplement and as a medical treatment.
This expanded body of research will likely fuel an equally explosive growth in the number of CBD products on the market. CBD water is the latest example of this growth.
Given how easy CBD water is to use, dose, and consume, CBD water could very well become the next big trend in cannabis.
I wandered over to a recent “cooking with cannabis” course hosted by Westville’s Women Grow CT to learn how to make some summer-themed edibles: lemonades, barbecue sauce, and the classic medley of baked goods. What I got was a glimpse into a budding industry.
“Has anyone heard of their endocannabinoid system?” Ellen Brown, cannabis education and activist, asked the room.
A few in the room of 10 audience members nodded or admitted to hearing about it, but waited for Brown to chime in with more facts and demonstrations before asking questions.
When making edibles, Ellen explained, if the dosage of drug is “10, 15 mg, that’s not a big deal. But if it’s 50 mg, 100mg, 300mg, 1000 mg,” then one must be mindful of dosage and how that edible will interact with our own endocannabinoid system.
Your endocannabinoid system, Brown said, is unique to your body. It is comprised of receptors in your brain and throughout your body that affect your emotions, movement, and reactions. The endocannabinoid system uses natural chemicals — cannabinoids— to interact with receptors in order to regulate those functions. Weed or cannabis interacts with the body in the same area.
The audience was a mix of advocates, caregivers, patients with mental and physical health concerns, and curious locals anticipating new laws. After a few rounds of questions, Brown took the stage as a marijuana savant.
“We’re building community here,” said Kebra Smith Bolden, Women Grow CT’s market leader. She made sure everyone was comfortable, hydrated, and ready to learn from Brown, her former teacher from Sinsemilla Seminars located in Boston. The two women have prompted a series of seminars at the Women Grow CT office in Westville. They said they seek to educate the community about safe cannabis practices and new recipes.
Brown said that the market potential for cannabis led her to move to California and join what’s being called the Green Rush — the expansion of weed-related industry as legalization has progressed across the country. During her time working in dispensaries and cultivation in California, Brown was prompted to make edibles, tinctures, and hashes from the excess materials. When life gives you excess cannabis, make infused lemonade.
At a cannabis cooking class, one may expect platters of concoctions drizzled in cannabutter and oils. Spreads of sweet gummies, brownies, cookies, candies to indulge in. However, with the current Connecticut laws surrounding cannabis use in place, our class simply imagined that the chocolate ganache we dipped our assorted fruits in was infused with cannabis.
Instead of a rehash of Bong Appetit, the biggest mouthfuls at Brown’s cooking class were lessons on endocannabinoid systems, arachidonoylglycel, anandamide, and a range of concerns and safety practices.
Brown went on to describe and explain the differences among cannabinoids like THC and CBD, as well as terpenes such as limonene and myrcene. Not a tasty combination of words, but as she suggested, they offered very important ways to understand the effects of different strains of marijuana. The different attributes of cannabis interact with one another, making for different aromas, flavors, and focuses on the body. It “can be dank, it can be really sweet, or somewhere in the middle,” she explained, but even so it was fair to ask, “why is it interacting with my body?”
Knowing your own body’s endocannabinoid system, Brown explained, could make the difference between a getting a good night’s sleep or going out for a five-mile run.
Before Brown taught us how to identify a good strain, the best ways to test, and the ways in which cannabis interacts with our bodies, she quizzed us— lightly. If growers and dispensaries were not aware of the specifics of the plant and products they sold, she reasoned, they are neglecting to provide sufficient and effective care.
Robert Specht of Hamden raised his hand. “I don’t think they — the growers — could answer any of your questions. They don’t know enough…. It’s just a product to them,” he said. A few people nodded in agreement. Specht said that he has been advocating for legalization for nine years and wanted those involved to educate themselves.
In between a lesson, I sneaked away to ask Bolden about why this seminar series was important. Why edibles?
Bolden told me that patients with prescriptions for medical marijuana vary and that “every method of consumption doesn’t work for everyone. Some can’t tolerate smoke.” As far as the edibles were concerned, although they were fun, Bolden understood them an opportunity for patients to “use their medicine in a new way, choose from options, and create different ways to consume.”
Much like the participants in the room, Kebra was concerned with the ways in which people obtained cannabis.
“When you’re on the street, you go by what people say. In a class, or just on your own — it forces you to educate yourself.”
I settled back into the room to hear about different ways to infuse cannabis, from almond oil to bacon grease to just lard. Eventually the room was filled with subtle puns, personal experiences, and dispensary tales.
Dorothy Lunhn drove the distance from Middletown to keep up with the latest information about medical marijuana. She currently works in the cannabis industry at the Arrow Alternative Care dispensary in Hartford and told me about her experiences as a caregiver and concerned friend. Lunhn explained that some of the challenge with providing care with cannabis in Connecticut was that “the state changes the law so frequently.” She mentioned later that evening that the dispensaries in Connecticut seldom gave much advice.
We finished the evening with a hands-on cooking demonstration, nibbling on some fruit with regular chocolate ganache.
As the state anticipates budget negotiations, possibly reintroducing a bipartisan effort to amend the law for recreational cannabis use for people 21 years or older as well as permit registered retailers, the cannabis cooking class anticipated a host of issues. Just to legalize, to grow, or to be able to use is it is not enough. The cooking class illuminated the conversation of legalizing cannabis in Connecticut by asking questions well beyond age restrictions. When the state House of Representatives debated legalization, Republican Rep. Vincent Candelora mentioned that in order to enact legislation we must see how it plays out in other states. Our class was ripe with news on Maine, Nevada, Minnesota, Massachusetts and ultimately concluded that limited knowledge on cannabis and an aversion to engage in the conversation on what legalization in Connecticut should look like are major issues. Julia Hawkins, from Hamden, explained that whatever regulation might be enacted should be as advocates imagine: “empowering and educational.”
Penny Stock General Cannabis Triggers Regulatory Scrutiny Over Promotional Concerns Cannabis stocks have been on quite the tear, with the index almost doubling from the levels near the end of August as traders gravitate to the sector in front of several state legalization initiatives next month. One of the big movers has been General Cannabis (OTC: CANN), which was formerly Advanced Cannabis Solutions. The company has several divisions, the largest of which provides security solutions in Colorado. From August 31st until its peak this morning, the stock had appreciated by over 500%. Today, though, it has given up a lot of those gains: The stock quickly lost more than 1/3 of its value after the company a press release detailing the concerns of OTC Markets, where its stock trades: On October 12, 2016, OTC Markets informed the Company that it became aware of certain promotional activities concerning General Cannabis and its common stock. OTC Markets informed the company that it had received copies of promotional newsletter emails encouraging investors to purchase the Company’s common stock. The Green Rush Company has been informed that this promotional activity coincided with higher than average trading volume in the Company’s stock. The Company was unaware of the promotional activity until informed by OTC Markets and is unaware of the full nature and content of this promotional activity, the responsible parties and the extent of the email newsletters’ dissemination. The company’s CEO, Robert Frichtel, who filed a Form 144 to sell 100K shares and has sold 25K shares yesterday (not yet reported to SEC with a Form 4), stated that the company was not aware of the promotional activity until being alerted by OTC Markets. In early 2014, CANN was the first major cannabis stock to be suspended from trading by the SEC due to the activities of an unaffiliated third-party. The company later regained its OTCQB listing. Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.
The other issue is that a cannabis shortage provides the perfect opportunity for the black market to step in and illegally fill the gap. Trudeau has already proposed low taxes to keep pricing comparable between legal and black market weed, but if there’s not enough supply, there’s little that can be done. Even with the four Canadian producers listed above expanding their grow capacity considerably, it’d be a stretch to assume that all four will be up and running at full steam by July 2018. Here’s the not-so-secret reason why Canada has this odd marijuana issue Recently, Health Canada announced a number of changes to its medical marijuana program. With just 44 licenses issued, the regulatory agency that’s in charge of overseeing the welfare of its country’s citizens announced that it would approve more grow licenses and allow pot producers to Medical marijuana stocks essentially fill up their vaults as long as it could be done safely and securely. On the surface, this move by Health Canada seems to be a reaction to the idea that recreational marijuana could soon be approved. But dig a bit deeper and you’ll find there’s more to it than that. The real reason we could witness a marijuana shortage if Canada’s recreational weed bill passes is because a handful of Canadian medical cannabis producers have been exporting their product overseas. There are more than two dozen countries in the world with legal medical cannabis programs, but only Canada and the Netherlands have producers that are legally allowed to export their product to these countries. There are four Canadian producers that are currently exporting, including Canopy Growth, Aphria, Cronos Group, and Tilray. Germany provides the perfect example.
It’s an exciting space to invest, though it’s clearly not risk-free with the federal government still looming. Wisely, SMG avoids the higher risk aspects of handling the substance, instead focusing on the lower-risk opportunity to simply supply the booming hydroponics industry. There are obvious similarities between today’s proliferation of “pot stocks” and the California Gold Rush of 1849. Not every prospector will make it. But the companies supplying those prospectors? That was where the smart money went in 1849 – the same is true today. Following the big money, like SMG, it’s clear why they’re investing heavily in the ability to “sell shovels” to cannabis handlers. SMG’s Hawthorne subsidiary and gardening segment accounted for about 13% of net sales last year, or $365 million, and the company reported 30% revenue growth from Hawthorne over the previous year. This was Hawthorne’s second full year in business. Solis Tek (OTCMKTS:SLTK) takes the same approach. The company is a manufacturer of digital lighting equipment (called “grow lights”) for the hydroponics industry. Solis Tek is one of these custom light providers, producing ballasts, reflectors, and Marijuana Stocks HID lights, with some of the most respected custom products on the market; Dope Magazine dubbed Solis Tek 2016’s “Best Lighting Company.” It may not sound as sexy as medicinal pot growing companies, but the market potential, and Solis Tek’s current growth and financials, are fundamentally sound.
“Our investors very much fit that mold: they are high net worth individuals and they are family offices. We’ve got a total of about 40 to 45 investors who provide funding to our venture funds … and we protect them from immature entrepreneurs who are unable to get out of their own way.” We then moved on to discuss a few Canopy alumni who were not pleased with the results following the boot camp. “We make a lot of investments so I fully expect that 5 percent or 10 percent of our investments are going to go south and they’re going to end up failing. Sometimes those will cause some heartburn with different people,” the managing director answered. But, does he stand by his choice of selecting them to be a part of the Canopy program notwithstanding? Or does Tapman look back at it as a mistake? “I think it’s very easy to pretend like we made a mistake selecting some companies, but the reality is that you make decisions based on data that you have available at the time,” he said, sharing a sports metaphor. When a team wants to recruit a new athlete, it’s usually better to find a young man or woman with potential and invest in his/her future, instead of acquiring an extremely expensive, acclaimed athlete.
To read more visit Medical marijuana stocks href=’https://www.benzinga.com/news/17/06/9658646/pot-baron-on-canopyboulders-investments-we-focus-on-cos-that-can-scale-to-spectac’ rel=’nofollow’>https://www.benzinga.com/news/17/06/9658646/pot-baron-on-canopyboulders-investments-we-focus-on-cos-that-can-scale-to-spectac
Under the Obama administration, Attorney General James Cole issued a memo outlining the federal government’s priorities on marijuana enforcement. It instructed Justice Department attorneys and law enforcement to “focus their enforcement resources and efforts, including prosecution, on persons or organizations whose conduct interferes with any one or more of these priorities, regardless of state law”. You read that right, the Cole memo leaves the door open for federal enforcement, but these are the specific priorities the memo said the federal government should focus on preventing: Revenue from the sale of marijuana from going to criminal enterprises, gangs, and cartels The diversion Green Rush of marijuana from states where it is legal under state law in some form to other states State-authorized marijuana activity from being used as a cover or pretext for the trafficking of other illegal drugs or other illegal activity Violence and the use of firearms in the cultivation and distribution of marijuana Drugged driving and the exacerbation of other adverse public health consequences associated with marijuana use The growing of marijuana on public lands and the attendant public safety and environmental dangers posed by marijuana production on public lands Marijuana possession or use on federal property Canada legalized marijuana for medical use in 1999. Medical use faced tight regulations at first, but those have loosened over time. Now Prime Minister Justin Trudeau is following through on one of his campaign promises. He recently introduced legislation to legalize recreational marijuana use and, if all goes according to plan, the Canadian government hopes to allow legal sales by the middle of next year. Canada’s proposed law requires purchasers to be at least 18 years old and limits the amount you can have to 30 grams, which is close to the recreational use amounts allowed in Colorado and California. The Canadian government will license and supervise commercial growers, similar to the current regulations they have in place for the cultivation of medical marijuana. The proposed law would eliminate certain legal risks for Canadian companies that American companies are still exposed to. There are pharmaceutical companies developing cannabis-based treatments for a variety of uses. Several have developed marijuana-based treatments that have been approved by the Food and Drug Administration (FDA), and others are in the process.
On top of the skyrocketing stock price, the dividend payout has increased for 13 years straight. And the profits from the second marijuana stock with dividends we are about to show you are even more staggering. A $10,000 investment in this stock on Dec. 31, 1997, Medical marijuana with the dividends reinvested would now be worth $85,572.14. In comparison, the shares would only be worth $70,585.55 if the dividends weren’t reinvested. That means reinvesting dividends would’ve boosted your return by 21%. This stock has climbed 451% since it traded for $15.13 per share on Dec. 31, 1997. On top of that, this company has increased its dividend payout for the last seven years.